330 Nuclear Medicine Physics
176. B. Gagel, P. Reinartz, C. Demirel, H. J. Kaiser, M. Zimny, M. Piroth, M. Pinkawa,
S. Stanzel, B. Asadpour, K. Hamacher, H. Coenen, U. Buell, M. J. Eble. 18F fluo-
romisonidazole and [18F] fluorodeoxyglucose positron emission tomography in
response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a
feasibility study. BMC Cancer, 6:51–59, 2006.
177. M. Yoshimoto, S. Kinuya, A. Kawashima, R. Nishii, K. Yokoyam, K. Kawai.
Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft
model. Nucl. Med. Biol., 33:963–969, 2006.
178. J. Toretsky, A. Levenson, I. N. Weinberg, J. F. Tait, A. Uren, R. C. Mease. Prepara-
tion of F-18 labeled annexin V: Apotential PET radiopharmaceutical for imaging
cell death. Nucl. Med. Biol., 31:747–752, 2004.
179. L. Aloj, A. Zannetti, C. Caracó, S. Del Vecchio, M. Salvatore. Bcl-2 overexpression
prevents 99mTc-MIBI uptake in breast cancer cell lines. Eur. J. Nucl. Med. Mol.
Imag., 31:521–527, 2004.
180. S. Del Vecchio, M. Salvatore. 99mTc-MIBI in the evaluation of breast cancer
biology. Eur. J. Nucl. Med. Mol. Imag., 31(Suppl. 1):S88–S96, 2004.
181. S. DelVecchio, A. Ciarmiello, M. I. Potena, M. V. Carriero, C. Mainolfil, G. Botti,
R. Thomas, M. Cerra, G. D’Aiuto, T. Tsuruo, M. Salvatorel. In vivo detection of
multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in
untreated breast cancer patients. Eur. J. Nucl. Med., 24:150–159, 1997.
182. S. Kinuya, J. Bai, K. Shiba, K. Yokoyama, H. Mori, M. Fukuoka, N. Watanabe,
N. Shuke, T. Michigishi, N. Tonami. 99mTc-sestamibi to monitor treatment with
antisense oligodeoxynucleotide complementary to MRP mRNAin human breast
cancer cells. Ann. Nucl. Med., 20:29–34, 2006.
183. N. H. Hendrikse, E. J. F. Franssen, WTA. van der Graaf, W. Vaalburg, E. G. E. de
Vries. Visualization of multidrug resistance in vivo. Eur. J. Nucl. Med., 26:283–293,
1999.
184. J. R. Murren. Modulating multidrug resistance: Can we target this therapy? Clin.
Cancer Res., 8:633–635, 2002.
185. W. Guo, G. H. Hinkle, R. J. Lee. 99mTc-HYNIC-Folate: A novel receptor-based
targeted radiopharmaceutical for tumor imaging. J. Nucl. Med., 40:1563–1569,
1999.
186. I. Madar, B. Bencherif, J. Lever, R. F. Heitmiller, S. C. Yang, M. Brock, J. Brahmer,
H. Ravert, R. Dannals, J. J. Frost. Imaging δ- and μ-opioid receptors by PET in
lung carcinoma patients. J. Nucl. Med., 48:207–213, 2007.
187. M. Mirowski, R. Wiercioch, A. Janecka, E. Balcerczak, E. Byszewska, D. Birn-
baum, S. Byzia, P. Garnuszek, R. Wierzbickia. Uptake of radiolabeled morphi-
ceptin and its analogs by experimental mammary adenocarcinoma: In vitro and
in vivo studies. Nucl. Med. Biol., 31:451–457, 2004.
188. C. Zeng, S. Vangveravong, J. Xu, K. C. Chang, R. S. Hotchkiss, K. T. Wheeler, D.
Shen, Z. P. Zhuang, H. F. Kung, R. H. Mach. Subcellular localization of Sigma-
2 receptors in breast cancer cells using two-photon and confocal microscopy.
Cancer Res., 67:6708–6716, 2007.
189. E. Bombardieri, F. Crippa, L. Maffioli, M. Greco. Nuclear medicine techniques
for the study of breast cancer. Eur. J. Nucl. Med., 24:809–824, 1997.
190. F. G. Blankenberg, H. W. Strauss. Nuclear medicine applications in molecular
imaging. J. Mag. Res. Imaging, 16:352–361, 2002.
191. D. J. Hnatowich. Observations on the role of nuclear medicine in molecular
imaging. J. Cell. Biochem., Suppl. 39:18–24, 2002.